-$0.67 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter

Analysts predict that Proteostasis Therapeutics Inc (NASDAQ:PTI) will announce earnings per share of ($0.67) for the current quarter, Zacks reports. Two analysts have made estimates for Proteostasis Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.72). Proteostasis Therapeutics reported earnings per share of ($0.38) during the same quarter last year, which would suggest a negative year-over-year growth rate of 76.3%. The business is expected to report its next earnings report on Thursday, March 29th.

According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.50) per share for the current year, with EPS estimates ranging from ($2.56) to ($2.44). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.36) per share, with EPS estimates ranging from ($2.82) to ($1.89). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its earnings results on Tuesday, November 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. The firm had revenue of $1.55 million during the quarter, compared to analysts’ expectations of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%.

PTI has been the subject of a number of recent analyst reports. Leerink Swann upped their target price on Proteostasis Therapeutics from $6.00 to $8.00 in a research report on Tuesday, December 12th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a research report on Tuesday, December 19th. Zacks Investment Research raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird increased their price objective on Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Finally, ValuEngine raised Proteostasis Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $16.00.

In related news, major shareholder Enterprise Associates 12 New acquired 2,000,000 shares of the company’s stock in a transaction on Monday, December 18th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $10,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Cormorant Asset Management, Ll sold 504,027 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $4.88, for a total value of $2,459,651.76. The disclosure for this sale can be found here. Insiders purchased 2,100,000 shares of company stock valued at $10,500,000 over the last 90 days. 17.40% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new position in Proteostasis Therapeutics during the second quarter worth $254,000. FMR LLC raised its stake in Proteostasis Therapeutics by 2.3% during the second quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after acquiring an additional 66,111 shares in the last quarter. Jennison Associates LLC raised its stake in Proteostasis Therapeutics by 53.5% during the fourth quarter. Jennison Associates LLC now owns 3,178,432 shares of the company’s stock worth $18,530,000 after acquiring an additional 1,107,496 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Proteostasis Therapeutics during the second quarter worth $296,000. Finally, Sabby Management LLC raised its stake in Proteostasis Therapeutics by 109.6% during the second quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after acquiring an additional 65,451 shares in the last quarter. Hedge funds and other institutional investors own 55.15% of the company’s stock.

Shares of Proteostasis Therapeutics (PTI) opened at $2.96 on Monday. Proteostasis Therapeutics has a 12-month low of $1.41 and a 12-month high of $16.67.

COPYRIGHT VIOLATION NOTICE: “-$0.67 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.themarketsdaily.com/2018/02/15/0-67-earnings-per-share-expected-for-proteostasis-therapeutics-inc-pti-this-quarter.html.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply